The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF for recipients with previous transplants. In this study, we analyzed patients who received previous transplants, treated with the above immunosuppressive regimen. Group A consisted of four patients with previous liver transplants, group B consisted of 16 recipients with previous kidney transplants and group C consisted of three patients with previous simultaneous pancreas-kidney transplants. All patients underwent cadaveric kidney transplants except one patient in group B, who underwent a pancreas transplant. At 12 months, patient and graft survival for all groups was 100 and 100%, respectively. Acute rejection rate was 0% for group A, 12.5% for group B, and 0% for group C. Daclizumab induction therapy is effective for patients with previous transplants and does not appear to increase the risk of acute rejection.

Original languageEnglish
Pages (from-to)428-432
Number of pages5
JournalClinical Transplantation
Volume17
Issue number5
DOIs
StatePublished - Oct 1 2003

Fingerprint

Mycophenolic Acid
Tacrolimus
Transplants
Therapeutics
Kidney
Pancreas
daclizumab
Organ Transplantation
Graft Survival
Immunosuppressive Agents
Clinical Trials
Liver
Incidence

Keywords

  • Acute rejection
  • Induction therapy
  • Mycophenolate mofetil
  • Previous transplants
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

@article{c33f844911cc439a8d4c136b70884e11,
title = "The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants",
abstract = "Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF for recipients with previous transplants. In this study, we analyzed patients who received previous transplants, treated with the above immunosuppressive regimen. Group A consisted of four patients with previous liver transplants, group B consisted of 16 recipients with previous kidney transplants and group C consisted of three patients with previous simultaneous pancreas-kidney transplants. All patients underwent cadaveric kidney transplants except one patient in group B, who underwent a pancreas transplant. At 12 months, patient and graft survival for all groups was 100 and 100{\%}, respectively. Acute rejection rate was 0{\%} for group A, 12.5{\%} for group B, and 0{\%} for group C. Daclizumab induction therapy is effective for patients with previous transplants and does not appear to increase the risk of acute rejection.",
keywords = "Acute rejection, Induction therapy, Mycophenolate mofetil, Previous transplants, Tacrolimus",
author = "Gaetano Ciancio and Mattiazzi, {Adela D} and David Roth and Warren Kupin and Joshua Miller and Burke, {George W}",
year = "2003",
month = "10",
day = "1",
doi = "10.1034/j.1399-0012.2003.00066.x",
language = "English",
volume = "17",
pages = "428--432",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

AU - Ciancio, Gaetano

AU - Mattiazzi, Adela D

AU - Roth, David

AU - Kupin, Warren

AU - Miller, Joshua

AU - Burke, George W

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF for recipients with previous transplants. In this study, we analyzed patients who received previous transplants, treated with the above immunosuppressive regimen. Group A consisted of four patients with previous liver transplants, group B consisted of 16 recipients with previous kidney transplants and group C consisted of three patients with previous simultaneous pancreas-kidney transplants. All patients underwent cadaveric kidney transplants except one patient in group B, who underwent a pancreas transplant. At 12 months, patient and graft survival for all groups was 100 and 100%, respectively. Acute rejection rate was 0% for group A, 12.5% for group B, and 0% for group C. Daclizumab induction therapy is effective for patients with previous transplants and does not appear to increase the risk of acute rejection.

AB - Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF for recipients with previous transplants. In this study, we analyzed patients who received previous transplants, treated with the above immunosuppressive regimen. Group A consisted of four patients with previous liver transplants, group B consisted of 16 recipients with previous kidney transplants and group C consisted of three patients with previous simultaneous pancreas-kidney transplants. All patients underwent cadaveric kidney transplants except one patient in group B, who underwent a pancreas transplant. At 12 months, patient and graft survival for all groups was 100 and 100%, respectively. Acute rejection rate was 0% for group A, 12.5% for group B, and 0% for group C. Daclizumab induction therapy is effective for patients with previous transplants and does not appear to increase the risk of acute rejection.

KW - Acute rejection

KW - Induction therapy

KW - Mycophenolate mofetil

KW - Previous transplants

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=0141990520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141990520&partnerID=8YFLogxK

U2 - 10.1034/j.1399-0012.2003.00066.x

DO - 10.1034/j.1399-0012.2003.00066.x

M3 - Article

C2 - 14703925

AN - SCOPUS:0141990520

VL - 17

SP - 428

EP - 432

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

ER -